As the investment division of Viva Biotech , Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 month, our portfolio companies have had great progress.
Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation
On May 18, 2022, Anji Pharma, an emerging global medicines company which invested and incubated by Viva BioInnovator, announced it has completed enrollment in its Phase 2 proof of concept study of pradigastat (ANJ908), a diacylglycerol acyltransferase 1 (DGAT1) inhibitor, in patients with functional constipation. Anji plans to report topline data from this study in the second half of 2022.
AIxplorerBio Entered A Broad Collaboration with Baidu’s PaddleHelix to Expedite the Construction of Its AI Small Molecule Drug R＆D Platform
On May 18, AIxplorerBio, a Viva BioInnovator portfolio company, announced a broad collaboration with PaddleHelix. The two parties will leverage their strengths and collaborate in the fields of de novo molecular design and druggability evaluation, to accelerate new AI-powered drug research and development platform. The collaboration takes fully advantage of PaddleHelix's strengths in AI technologies and AIxplorerBio's experience in new drug R＆D and experiemental capabilities to jointly develop AI-powered drug discovery models. Dr. David. Xu, CEO of AIxplorerBio, emphasized, "AIxplorerBio is an AI-powered, structure-based drug R&D biotech company. The collaboration with Baidu's PaddleHelix will help enhance our new AI drug R＆D platform - AIxMolTM, and speed up the development of our pipeline.”
Domain Therapeutics Raises $42m Series A Financing
On May 10, Domain Therapeutics, a biopharmaceutical company specializing in the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology, announced the closing of a US $42m (€39m) series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners.
VivaVision Announces That VVN539 Has Been Formally Submitted for U.S. Phase II Clinical Trial Application
VivaVision, an innovative ophthalmic drug company which invested and incubated by Viva BioInnovator, announced that it has submitted a Phase II clinical trial application for the new drug VVN539 for the treatment of open-angle glaucoma to the FDA on May 5, 2022, and will start the clinical study in June 2022.
VVN539 is a new generation, dual-targeted IOP-lowering drug that acts on the trabecular meshwork of the eye to increase the outflow of aqueous humor, thereby reducing IOP. In preclinical animal models, VVN539 has shown excellent IOP-lowering efficacy.
ArrePath Announces Appointment of Dr. Bret Benton as Vice President of Microbiology
ArrePath, an anti-infective drug discovery company addressing the global health challenge of drug resistant infections, which invested and incubated by Viva BioInnovator, recently announced that a new appointment of Dr. Bret Benton as Vice President, Microbiology.
Bret will become part of ArrePath's senior leadership team, leading their Princeton based operations, bringing a wealth of expertise to company in applying imaging and machine learning technologies to the discovery and development of new classes of anti-infectives.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号
- About Us
-
CRO Services
BackCRO ServicesDiscovery Biology Services
- CDMO Services
- EFS Business
- News
- Careers
- Investor Relations
- Contact Us